HOWL Werewolf Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1785530 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY61.4%
TTM EPS YoY63.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-154.6%
ROA-46.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets84.2%
Debt / equity0.00x
Current ratio1.19x
Interest coverage-7.97x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.17M | $6.16M | $8.18M | $6.93M | $11.63M | $13.14M | $13.12M | $15.73M |
| SG&A expense | $7.88M | $7.68M | $5.09M | $2.48M | $4.09M | $4.40M | $4.87M | $4.62M |
| Operating income | -$10.05M | $7.16M | -$13.27M | -$9.42M | -$15.73M | -$17.54M | -$17.99M | -$20.35M |
| Interest expense | $0 | $475,000 | $1.37M | $1.37M | $1.34M | $1.30M | $1.26M | $1.27M |
| Net income | -$9.88M | $3.67M | -$13.53M | -$8.38M | -$16.37M | -$17.98M | -$18.09M | -$20.40M |
| EBITDA | -$8.79M | $9.61M | -$12.87M | -$9.02M | -$15.32M | -$17.14M | -$17.57M | -$19.91M |
| EPS (basic) | -0.20 | 0.08 | -0.28 | — | -0.36 | -0.40 | -0.40 | — |
| EPS (diluted) | -0.20 | 0.08 | -0.28 | — | -0.36 | -0.40 | -0.40 | — |
| Weighted avg. shares (diluted) | 48.60M | 48.60M | 49.39M | — | 45.80M | 44.98M | 44.83M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.87M | $21.99M | $46.45M | $57.05M | $65.71M | $77.60M | $92.04M | $112.22M |
| Current assets | $42.75M | $22.89M | $48.73M | $58.59M | $68.17M | $80.44M | $94.46M | $113.07M |
| PP&E, net | $0 | $1.26M | $4.29M | $4.69M | $5.09M | $5.49M | $5.90M | $6.32M |
| Total assets | $42.75M | $24.16M | $58.02M | $69.40M | $79.63M | $92.57M | $107.24M | $126.93M |
| Current liabilities | $35.99M | $7.86M | $38.52M | $36.15M | $17.60M | $15.17M | $11.67M | $15.18M |
| Long-term debt | — | — | $32.09M | $32.09M | $32.09M | $32.09M | $32.09M | $32.09M |
| Total debt | — | — | $32.09M | $32.09M | $32.09M | $32.09M | $32.09M | $32.09M |
| Total liabilities | $35.99M | $7.86M | $45.82M | $44.59M | $50.01M | $51.10M | $49.93M | $53.54M |
| Shareholders' equity | $6.76M | $16.29M | $12.20M | $24.80M | $29.61M | $41.46M | $57.31M | $73.39M |
| Net debt | — | — | -$14.37M | -$24.96M | -$33.63M | -$45.51M | -$59.96M | -$80.13M |
| Shares outstanding | 48.60M | 48.60M | 48.60M | 48.60M | 47.27M | 45.34M | 44.83M | 44.83M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.97M | $6.63M | -$10.60M | -$11.02M | -$15.16M | -$15.16M | -$18.95M | -$14.25M |
| Capital expenditure | — | — | — | $0 | $0 | $0 | $0 | $123,000 |
| Free cash flow | — | — | — | -$11.02M | -$15.16M | -$15.16M | -$18.95M | -$14.38M |
| Investing cash flow | $28.85M | — | — | $0 | $0 | $0 | $0 | -$123,000 |
| Financing cash flow | $0 | — | — | $2.37M | $3.27M | $388,000 | $0 | $2.55M |
| Depreciation & amortization | $1.26M | $2.45M | $398,000 | $400,000 | $402,000 | $406,000 | $426,000 | $442,000 |
| Stock-based compensation | $344,000 | $419,000 | $929,000 | $1.21M | $1.23M | $1.79M | $2.01M | $1.91M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.